Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accounts Payables: 2010-2025

Historic Accounts Payables for Ironwood Pharmaceuticals (IRWD) over the last 14 years, with Sep 2025 value amounting to $1.6 million.

  • Ironwood Pharmaceuticals' Accounts Payables fell 50.15% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 50.15%. This contributed to the annual value of $2.1 million for FY2024, which is 72.84% down from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Accounts Payables stood at $1.6 million, which was up 16.13% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Accounts Payables ranged from a high of $7.8 million in Q4 2023 and a low of $118,000 during Q1 2023.
  • In the last 3 years, Ironwood Pharmaceuticals' Accounts Payables had a median value of $3.2 million in 2024 and averaged $3.6 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Accounts Payables slumped by 79.01% in 2021 and then soared by 5,172.88% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Accounts Payables stood at $935,000 in 2021, then crashed by 48.34% to $483,000 in 2022, then spiked by 1,521.12% to $7.8 million in 2023, then crashed by 72.84% to $2.1 million in 2024, then plummeted by 50.15% to $1.6 million in 2025.
  • Its Accounts Payables stands at $1.6 million for Q3 2025, versus $1.4 million for Q2 2025 and $5.8 million for Q1 2025.